Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound. The pharma company ...

Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

In addition, the results showed that it has the potential to compete with Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). Amgen expects its revenue to be between $34.3 billion ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now. By Rebecca Robbins It’s easy to make a medical case for ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Amgen said it has started two critical late ... That's unlike Eli Lilly's obesity drug, Zepbound, which activates both GIP and GLP-1. Novo Nordisk's Wegovy activates GLP-1 but does not target ...

Lilly makes tirzepatide, commercialized under the name Zepbound for weight loss and Mounjaro for type ... GLP-1 receptor ...

Amgen’s stock has been rising consistently ... s LLY and Novo Nordisk’s NVO popular GLP-1-based obesity drugs, Zepbound and Wegovy, which are weekly injections.